Last reviewed 2026-05-30 · How we verify

Valacyclovir celecoxib dose 1

Bateman Horne Center · Phase 2 active Small molecule ✓ Verified May 2026

Valacyclovir celecoxib dose 1 is a Small molecule drug developed by Bateman Horne Center. It is currently in Phase 2 development. Also known as: Arm 1, Arm 2.

Celecoxib is a small molecule cyclooxygenase-2 inhibitor, classified as an INHIBITOR, which targets Prostaglandin G/H synthase 2. Valacyclovir is being studied in a clinical trial, SHIELD, for its potential to inhibit SARS-CoV-2 and herpesvirus, but no dose information is available for the specific condition of Post-acute Sequelae of COVID-19.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Valacyclovir celecoxib dose 1
Also known as	Arm 1, Arm 2
Sponsor	Bateman Horne Center
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2 (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Valacyclovir celecoxib dose 1 CI brief — competitive landscape report
Valacyclovir celecoxib dose 1 updates RSS · CI watch RSS
Bateman Horne Center portfolio CI

Frequently asked questions about Valacyclovir celecoxib dose 1

What is Valacyclovir celecoxib dose 1?

Valacyclovir celecoxib dose 1 is a Small molecule drug developed by Bateman Horne Center.

Who makes Valacyclovir celecoxib dose 1?

Valacyclovir celecoxib dose 1 is developed by Bateman Horne Center (see full Bateman Horne Center pipeline at /company/bateman-horne-center).

Is Valacyclovir celecoxib dose 1 also known as anything else?

Valacyclovir celecoxib dose 1 is also known as Arm 1, Arm 2.

What development phase is Valacyclovir celecoxib dose 1 in?

Valacyclovir celecoxib dose 1 is in Phase 2.

Manufacturer: Bateman Horne Center — full pipeline
Also known as: Arm 1, Arm 2

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing